Phase 4
N=11
Using Clonidine to Improve Leg Weakness in People With Heart Failure
Heart Failure
Bottom Line
View on ClinicalTrials.gov: NCT00858845 ↗Enrolled (actual)
11
Serious AEs
0.0%
Results posted
Sep 2013
Primary outcome: Primary: Change in Citrate Synthase Activity as an Estimate of Mitochondrial Activity — -0.3; 0.07 micromole/min/wet weight
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Clonidine Patch (Drug); Matching Placebo Patch (Other)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- University of California, Los Angeles
- Primary completion
- Mar 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Citrate Synthase Activity as an Estimate of Mitochondrial Activity |
-0.3; 0.07 | — |
| SECONDARY Change in Proportion of Type 1 Fibers |
-4.6; -5.6 | — |
Summary
People with heart failure often have weakness in their leg muscles. This study will determine whether the leg weakness is due to very high adrenaline levels and whether the medication clonidine can improve leg weakness.
Eligibility Criteria
Inclusion Criteria
- Heart failure
Exclusion Criteria
- Currently on Coumadin therapy
- Experienced a heart attack in the 3 months before study entry
- Medically unable to receive clonidine
- Advanced kidney or liver disease
Data sourced from ClinicalTrials.gov (NCT00858845). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.